Hortobagyi GN - Search Results

1

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Schott AF, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30. Breast Cancer Res Treat. 2016. PMID: 27475087 Free PMC article. Clinical Trial.

2

Overview of new treatments for breast cancer.

Hortobagyi GN. Hortobagyi GN. Breast Cancer Res Treat. 1992;21(1):3-13. doi: 10.1007/BF01811959. Breast Cancer Res Treat. 1992. PMID: 1356516

3

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Walters RS, et al. Among authors: hortobagyi gn. Invest New Drugs. 1992 Apr;10(1):43-4. doi: 10.1007/BF01275480. Invest New Drugs. 1992. PMID: 1376723 Clinical Trial.

4

Bone metastasis in breast cancer.

Theriault RL, Hortobagyi GN. Theriault RL, et al. Among authors: hortobagyi gn. Anticancer Drugs. 1992 Oct;3(5):455-62. doi: 10.1097/00001813-199210000-00002. Anticancer Drugs. 1992. PMID: 1450438 Review.

5

Activity of ifosfamide in breast cancer.

Hortobagyi GN. Hortobagyi GN. Semin Oncol. 1992 Dec;19(6 Suppl 12):36-41. Semin Oncol. 1992. PMID: 1485173 Review.

6

Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma.

Singletary SE, McNeese MD, Hortobagyi GN. Singletary SE, et al. Among authors: hortobagyi gn. Cancer. 1992 Jun 1;69(11):2849-52. doi: 10.1002/1097-0142(19920601)69:11<2849::aid-cncr2820691134>3.0.co;2-p. Cancer. 1992. PMID: 1571916

7

Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.

Ziegler LD, Connelly JH, Frye D, Smith TL, Hortobagyi GN. Ziegler LD, et al. Among authors: hortobagyi gn. Cancer. 1991 Aug 1;68(3):628-33. doi: 10.1002/1097-0142(19910801)68:3<628::aid-cncr2820680331>3.0.co;2-3. Cancer. 1991. PMID: 1648436

8

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Holmes FA, et al. Among authors: hortobagyi gn. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. doi: 10.1093/jnci/83.24.1797-a. J Natl Cancer Inst. 1991. PMID: 1683908 Clinical Trial.

9

Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas.

Katz RL, Patel S, Sneige N, Fritsche HA Jr, Hortobagyi GN, Ames FC, Brooks T, Ordonez NG. Katz RL, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1990 May;15(3):191-203. doi: 10.1007/BF01806356. Breast Cancer Res Treat. 1990. PMID: 1695528

10

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.

Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Buzdar AU, et al. Among authors: hortobagyi gn. Cancer. 1992 Jan 15;69(2):448-52. doi: 10.1002/1097-0142(19920115)69:2<448::aid-cncr2820690229>3.0.co;2-k. Cancer. 1992. PMID: 1728373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,102 results

Search Page